Price (delayed)
$10.66
Market cap
$526.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.04
Enterprise value
$824.03M
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases.
There are no recent dividends present for AERI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.